Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome

Journal of Clinical Psychiatry

Volumn 58, Issue SUPPL. 7, 1997, Pages 23-27

  Schatzberg, Alan F ^g   Haddad, Peter ^a   Kaplan, Eric M ^b   Lejoyeux, Michel ^c   Rosenbaum, Jerrold F ^d   Young, A H ^e   Zajecka, John ^f  

^a Prestwich Hospital   (United Kingdom)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c BICHAT HOSPITAL   (France)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^f RUSH UNIVERSITY MEDICAL CENTER   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

DEPRESSION; HUMAN; NAUSEA; NEUROTRANSMISSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SENSORY DYSFUNCTION; SEROTONIN BRAIN LEVEL; SLEEP DISORDER; VOMITING; WITHDRAWAL SYNDROME;

DOWN-REGULATION; HALF-LIFE; HUMANS; NEUROTRANSMITTER AGENTS; NOREPINEPHRINE; PAROXETINE; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SUBSTANCE WITHDRAWAL SYNDROME; SYNDROME;

EID: 0030795706     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996;16:356-362
2. Price JS, Waller PC, Wood SM, et al. A comparison of the post-markeling safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 1996;42:757-763
3. Dominguez RA, Goodnick PJ. Adverse events after the abrupt discontinuation of paroxetine. Pharmacotherapy 1995;15:778-780
4. Dubovsky S. Beyond the serotonin reuptake inhibitors: rationales for the development of new serotonergic agents. J Clin Psychiatry 1994; 55(2, suppl):34-44
5. Richelson E. The pharmacology of antidepressants at the synapse: focus on the newer compounds. J Clin Psychiatry 1994;55(9,suppl): 34-39
6. Bel N, Artigas F. In vivo effects of the simultaneous blockade of serotonin and norepinephrine transporters on serotonergic function: microdialysis studies. J Pharmacol Exp Ther 1996;278:1064-1072
7. Dilsaver SC, Greden JF, Snider RM. Antidepressant withdrawal syndromes: phenomenology and physiopathology. Int Clin Psychopharmacol 1987;2:1-19
8. Goodwin GM. How do antidepressants affect serotonin receptors? the role of serotonin receptors in the therapeutic and side effect profile of the SSRIs. J Clin Psychiatry 1996;57:9-13
9. Lane RM. Withdrawal symptoms after discontinuation of selective serotonin reuptake inhibitors (SSRIs). Journal of Serotonin Research 1996;3:75-83
10. Coccaro EF. Central serotonin and impulsive aggression. Br J Psychiatry 1989; 155(suppl 8):52-62
11. Bloch M, Stuger SV, Braun AR, et al. Severe psychiatric symptoms associated with paroxetine withdrawal [letter]. Lancet 1995;346:57
12. Jacobs BL, Fornal CA. 5-HT and motor control: a hypothesis. Trends Neurosci 1993;16:346-352
13. Frost L, Lal S. Shock-like sensations after discontinuation of selective reuptake inhibitors [letter]. Am J Psychiatry 1995;152:810
14. Rosenstock HA. Sertraline withdrawal in two brothers: a case report. Int Clin Psychopharmacol 1996;11:58-59
15. Pyke RE. Paroxetine withdrawal syndrome [letter]. Am J Psychiatry 1995;152:149-150
16. Lucot JB, Crampton GH. 8-OH-DPAT suppresses vomiting in the cat elicited by motion, cisplatin or xylazine. Pharmacol Biochem Behav 1989;33:627-631
17. Kaplan HI, Sadock BJ, eds. Comprehensive Textbook of Psychiatry, VI. 6th ed. Baltimore, Md.: Williams & Wilkins, 1995
18. Lazowick A. Potential withdrawal syndrome associated with SSRI discontinuation. Ann Pharmacother 1995;29:1284-1285
19. Lejoyeux M, Adés J, Mourad I, et al. Antidepressant withdrawal syndrome: recognition, prevention and management. CNS Drugs 1996;4: 278-292
20. Stoukides JA, Stoukides CA. Extrapyramidal symptoms upon discontinuation of fluoxetine [letter]. Am J Psychiatry 1991;148:1263
21. Louie A.K., Lannon RA, Ajari LJ. Withdrawal reactions after sertraline discontinuation [letter]. Am J Psychiatry 1994;151:450-451
22. Barr LC, Goodman WK, Price LH. Physical symptoms associated with paroxetine discontinuation [letter]. Am J Psychiatry 1994;151:289
23. Keuthen NJ, Cyr P, Ricciardi JA, et al. Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine [letter]. J Clin Psychopharmacol 1994;14:206-207
24. Mareth TR, Brown TM. SSRI withdrawal [letter with reply]. J Clin Psychiatry 1996;57:310
25. Committee on Safety of Medicines and Medicines Control Agency. Dystonia and withdrawal symptoms with paroxetine (Seroxat). Current Problems in Pharmacovigilance 1993;19:1
26. Phillips SD. A possible paroxetine withdrawal syndrome [letter]. Am J Psychiatry 1995;152:645-646
27. Pyke RE. Paroxetine withdrawal syndrome [letter]. Am J Psychiatry 1995;152:149-150
28. Fava GA, Grandi S. Withdrawal syndromes after paroxetine and sertraline discontinuation [letter]. J Clin Psychopharmacol 1995;15:374-375
29. Rauch SL, O'Sullivan RL, Jenike MA. Open treatment of obsessive-compulsive disorder with venlafaxine: a series of 10 cases [letter]. J Clin Psychopharmacol 1996;16:81-84